The c-Src inhibitor eCF506 diminishes opioid tolerance creating bias against β-arrestin2 recruitment

Abstract Opioids reduce severe pain, but persistent use is compromised by tolerance, attenuated by either β-arrestin2 depletion, prompting development of biased opioids limited by partial efficacy, or c-Src kinase inhibitors, potentially acting through off-target effects. We tested eCF506, a conformationally selective c-Src inhibitor, on morphine antinociception and examined its effect on μ receptor signaling and β-arrestin2 recruitment. Oral eCF506 inhibited morphine tolerance in C57BL/6J mice. Exposure of PathHunter CHO cells to eCF506 did not affect inhibition of cAMP accumulation by the μ agonist, DAMGO, but reduced β-arrestin2 recruitment. This effect, mimicked by targeted degradation of c-Src, occurred through inhibition of c-Src catalytic function as evidenced by its diminution by the catalytically inactive Src250-536(K298M) construct. This mutant also restricted the effect of c-Src inhibitors on β-arrestin2 recruitment. eCF506 additionally increased surface expression of μ receptors and limited their internalization by endomorphin-2 but did not alter DAMGO-evoked GRK-mediated receptor phosphorylation. These findings suggest that eCF506 prolongs opioid antinociception by inducing signalling bias, diminishing β-arrestin2-mediated μ receptor regulation.